Meningococcal vaccine development: a novel approach
- 23 February 1998
- journal article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 7 (2) , 245-252
- https://doi.org/10.1517/13543784.7.2.245
Abstract
Neisseria meningitidis is a major world-wide cause of meningitis. Effective capsular polysaccharide (CPS) vaccines that elicit CPS-specific bactericidal (BC) antibodies were previously developed and licensed to protect against meningococcal disease. However, due to their T-cell independent character, CPS vaccines are useless in infants and do not provide immunological memory or long-lasting protection in adults. CPS-protein conjugate vaccines are being developed to improve and broaden vaccine efficacy by creating T-cell dependent antigens. However, group B meningococci (GBM) are responsible for nearly half of meningococcal disease and possess a CPS, composed of polysialic acid, that is poorly immunogenic. N-propionyl (NPr) modification of the GBM polysaccharide (GBMP) has enhanced its immunogenicity, but BC antibodies are not induced at high levels, even when conjugated to conventional protein carriers, unless adjuvants stronger than aluminium hydroxide are used. We have chosen to couple the NPr-GBMP by reductive amination to a recombinant GBM class 3 porin (rPorB), which we have shown to modulate the immune response in animals towards the production of CPS-specific BC antibodies. We have also combined this conjugate with similar CPS-rPorB conjugates for groups A and C meningococci to form a trivalent A/B/C conjugate vaccine. This trivalent meningococcal vaccine has been shown to be safe and highly immunogenic in mice and non human primates, generating CPS-specific BC antibodies for each of the 3 major serogroups, which should provide world-wide protection against meningococcal disease.Keywords
This publication has 19 references indexed in Scilit:
- Preclinical Evaluation of a Novel Group B Meningococcal Conjugate Vaccine that Elicits Bactericidal Activity in both Mice and Nonhuman PrimatesThe Journal of Infectious Diseases, 1997
- Assessment of the Direct Effectiveness of BC Meningococcal Vaccine in Rio de Janeiro, Brazil: A Case-Control StudyInternational Journal of Epidemiology, 1995
- Epidemiology and prevention of meningococcal diseaseThe Pediatric Infectious Disease Journal, 1995
- Meningococcal disease: -- A review based on a symposium held on 11 July 1992 at the Liverpool School of Tropical MedicineJournal of Medical Microbiology, 1993
- Human Monoclonal Antibody with Protective Activity for Escherichia coli K1 and Neisseria meningitidis Group B InfectionsThe Journal of Infectious Diseases, 1987
- N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis.The Journal of Experimental Medicine, 1987
- ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITISThe Lancet, 1983
- Occurrence of α2–8 linked polysialosyl units in a neural cell adhesion moleculeBiochemical and Biophysical Research Communications, 1983
- Antibody Responses of Human Infants to Three Doses of Group A Neisseria meningitidis Polysaccharide Vaccine Administered at Two, Four, and Six Months of AgeThe Journal of Infectious Diseases, 1978
- Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.Journal of Clinical Investigation, 1975